Global Acute Pyelonephritis Market

Global Acute Pyelonephritis Market Insights Forecasts to 2035

• The Global Acute Pyelonephritis Market Size was valued at USD 199.1 Million in 2024
• The Global Acute Pyelonephritis Market Size is Expected to Grow at a CAGR of around 4.07% from 2025 to 2035
• The Worldwide Acute Pyelonephritis Market Size is Expected to Reach USD 308.9 Million by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

 

 

According to a research report published by Decisions Advisors and Consulting, the global acute pyelonephritis market size was worth around USD 199.1 Million in 2024 and is predicted to grow to around USD 308.9 Million by 2035 with a compound annual growth rate (CAGR) of 4.07% from 2025 to 2035. The global acute pyelonephritis market will develop through upcoming market pathways, which will result from increased demand for advanced antibiotics and rapid diagnostic tests, and emerging markets, and the growing number of elderly and diabetic patients, and the expansion of telemedicine-based healthcare services.

 

Market Overview

Acute pyelonephritis is a sudden and severe bacterial infection of the kidneys that needs immediate medical treatment to stop further health problems. The global acute pyelonephritis market is expanding steadily due to the increasing occurrence of urinary tract infections and the rising number of hospital admissions, and people becoming aware of early diagnosis and treatment methods. The market growth is supported by better treatment results, which come from rapid diagnostic technology improvements, advanced imaging techniques, and newly developed antibiotics. The demand for effective therapies is being driven by two factors: expanding healthcare systems in developing countries and increasing healthcare expenditures. Antimicrobial development, point-of-care testing, telemedicine-based follow-up systems, and customized treatment methods provide various business opportunities. The market will experience ongoing growth because of the rising number of elderly people and diabetic patients who face higher infection risks.

 

Report Coverage

This research report categorizes the acute pyelonephritis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the acute pyelonephritis market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the acute pyelonephritis market. 

 

Driving Factors

The global acute pyelonephritis market expands because of three main factors, which include rising urinary tract infection cases and increasing numbers of elderly people with reduced immunity and higher diabetes prevalence. The combination of public awareness and early detection methods leads to increased treatment consumption. The market expansion and patient health improvement stem from advancements in quick point-of-care testing and artificial intelligence-based imaging, and the creation of specific antibiotics and antimicrobial management solutions.

 

Restraining Factors

The global acute pyelonephritis market experiences main restrictions because of three major factors, which disrupt medical treatment through antibiotic resistance, create expensive treatment expenses, limit treatment access for low-income areas, and impose strict requirements for new drug approval processes.

 

Market Segmentation

The acute pyelonephritis market share is classified into type and pathogen type.

• The complicated acute pyelonephritis segment dominated the market in 2024, approximately 60%, and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the acute pyelonephritis market is divided into uncomplicated acute pyelonephritis and complicated acute pyelonephritis. Among these, the complicated acute pyelonephritis segment dominated the market in 2024, approximately 60%, and is projected to grow at a substantial CAGR during the forecast period. The higher clinical severity of patients leads to their increased need for hospital admission and intensive care treatment, which includes intravenous antibiotic administration. Patients with diabetes and kidney disorders, and weakened immunity, face higher risks of complications, which increases their need for advanced medical treatment. The segment generates higher revenue because of its extended hospital stays and increased treatment expenses, which maintain its ongoing market expansion.

• The escherichia coli segment accounted for the largest share in 2024, approximately 70% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the pathogen type, the acute pyelonephritis market is divided into escherichia coli, klebsiella pneumoniae, proteus mirabilis, and others. Among these, the escherichia coli segment accounted for the largest share in 2024, approximately 70% and is anticipated to grow at a significant CAGR during the forecast period. The main bacteria responsible for most urinary tract infections which lead to acute pyelonephritis constitute the main cause of the disease. The infection rates throughout the world rise because of its high occurrence and its potent disease-causing abilities and its ability to spread throughout local communities. The market share for E. coli infections continues to grow because of three factors which include frequent diagnosis and established treatment protocols and ongoing research to develop E. coli-specific antibiotics.

 

 Regional Segment Analysis of the Acute Pyelonephritis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the acute pyelonephritis market over the predicted timeframe.

North America is anticipated to hold the largest share of the acute pyelonephritis market over the predicted timeframe. The combination of advanced healthcare infrastructure, high public health awareness and early diagnosis capabilities and effective antibiotic treatments together with hospital services creates a healthcare system that enables better disease management. The market for this region will continue to grow because there are more urinary tract infections and the elderly population increases together with diabetes cases and the existing reimbursement systems and healthcare spending levels.

 

Asia-Pacific is expected to grow at a rapid CAGR in the acute pyelonephritis market during the forecast period. The United States market for urinary tract infection diagnostics will grow because of three factors. The first reason is the expansion of healthcare infrastructure which increases public recognition of urinary tract infections and provides better access to diagnostic tests and antibiotic treatments. The second reason for market growth is the United States population which includes both young and elderly people who have become more aware of their urinary tract infection symptoms. The third reason for market expansion is the increasing demand for testing because people now understand their urinary tract infection symptoms.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the acute pyelonephritis market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Pfizer Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Novartis AG
• Roche Holding AG
• GlaxoSmithKline (GSK)
• Sanofi S.A.
• Merck & Co., Inc. (MSD)
• AstraZeneca plc
• Bayer AG
• Abbott Laboratories
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the acute pyelonephritis market based on the below-mentioned segments: 

 

Global Acute Pyelonephritis Market, By Type

• Uncomplicated Acute Pyelonephritis
• Complicated Acute Pyelonephritis

 

Global Acute Pyelonephritis Market, By Pathogen Type

• Escherichia coli
• Klebsiella pneumoniae
• Proteus mirabilis
• Others

 

Global Acute Pyelonephritis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

Q1. What is driving growth in the acute pyelonephritis market?

A:  Growth is driven by rising urinary tract infection cases, increasing elderly and diabetic populations, stronger healthcare spending, wider antibiotic access, and innovations in rapid diagnostics, imaging technologies, and telemedicine-supported follow-up care services.

 

Q2. What market size is projected by 2035?

A:  According to Decisions Advisors and Consulting, the market is projected to reach USD 308.9 million by 2035, growing from USD 199.1 million in 2024 at a steady 4.07% compound annual growth rate.

 

Q3. Which segment leads by disease type?

A:  Complicated acute pyelonephritis leads due to severe clinical presentation, frequent hospitalizations, intensive intravenous antibiotic use, longer treatment duration, and higher medical costs, generating stronger revenue contribution than uncomplicated cases.

 

Q4. Which pathogen contributes most to cases?

A:  Escherichia coli dominates because it causes most urinary tract infections progressing to kidney infections, spreads easily in communities, and benefits from established diagnostic pathways, standardized therapies, and ongoing pathogen-targeted antibiotic research.

 

Q5. Which regions lead and grow fastest?

A:  North America leads due to advanced healthcare systems and high diagnosis rates, while Asia-Pacific grows fastest from expanding infrastructure, large patient pools, rising awareness, and increasing healthcare investments.